Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 2Not yet recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 1Neuroendocrine Tumors 1Cholangiocarcinoma 1

Interventions

Gemcitabine 42130-nm albumin-bound paclitaxel 26Albumin-Bound Paclitaxel 18Irinotecan 16Oxaliplatin 14Fluorouracil 14pembrolizumab 13Nivolumab 13Magnetic Resonance Spectroscopy 11Leucovorin 11Taxes 10Specimen Handling 9Biopsy 9Cisplatin 8Capecitabine 7folfirinox 6Radiotherapy 6Carboplatin 6irinotecan sucrosofate 5durvalumab 5Ipilimumab 5Cyclophosphamide 5olaparib 4defactinib 4Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Immunoglobulin G 4Disulfides 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Neoplasms × surufatinib × Clear all
NCT05908747 2026-02-10

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
29 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡